Adenocarcinoma of the endometrium

Survival comparisons of patients with and without pelvic node sampling

Larry Kilgore, Edward E. Partridge, Ronald D. Alvarez, J. Maxwell Austin, Hugh M. Shingleton, Frank Noojin, Wendy Conner

Research output: Contribution to journalArticle

451 Citations (Scopus)

Abstract

From 1969 to 1990, 649 patients with adenocarcinoma of the endometrium were surgically managed by gynecologic oncologists from the University of Alabama at Birmingham. All patients underwent TAH-BSO and washings. Two hundred twelve patients had multiple-site pelvic node sampling (mean number of nodes, 11), 205 patients had limited site pelvic node sampling (mean number of nodes, 4), and in 208 patients, nodes were not sampled. Historical prognostic features, including tumor grade, depth of invasion, adnexal metastasis, cervical involvement, and positive cytology, were equally distributed in the three groups. Mean follow-up was 3 years. Patients undergoing multiple-site pelvic node sampling had significantly better survival than patients without node sampling (P = 0.0002). When patients were categorized as low risk (disease confined to the corpus) or as high risk (disease in the cervix, adnexa, uterine serosa, or washings) multiple-site pelvic node sampling again provided a significant survival advantage compared to patients without node sampling (high risk, P = 0.0006; low risk, P = 0.026). In a comparison of patients receiving whole pelvic radiation for grade III lesions or deep myometrial invasion, patients with multiple-site pelvic node sampling had better survival than those in whom nodes were not sampled (P = 0.0027). The significant survival advantage for patients having multiple-site node sampling, overall and in high- and low-risk groups, strongly suggests a therapeutic benefit. Additionally, adjuvant therapy may be more appropriately directed in these patients.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalGynecologic oncology
Volume56
Issue number1
DOIs
StatePublished - Jan 1 1995

Fingerprint

Endometrium
Adenocarcinoma
Survival
Uterine Cervical Diseases
Serous Membrane
Cervix Uteri
Cell Biology
Radiation
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Kilgore, L., Partridge, E. E., Alvarez, R. D., Austin, J. M., Shingleton, H. M., Noojin, F., & Conner, W. (1995). Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. Gynecologic oncology, 56(1), 29-33. https://doi.org/10.1006/gyno.1995.1005

Adenocarcinoma of the endometrium : Survival comparisons of patients with and without pelvic node sampling. / Kilgore, Larry; Partridge, Edward E.; Alvarez, Ronald D.; Austin, J. Maxwell; Shingleton, Hugh M.; Noojin, Frank; Conner, Wendy.

In: Gynecologic oncology, Vol. 56, No. 1, 01.01.1995, p. 29-33.

Research output: Contribution to journalArticle

Kilgore, L, Partridge, EE, Alvarez, RD, Austin, JM, Shingleton, HM, Noojin, F & Conner, W 1995, 'Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling', Gynecologic oncology, vol. 56, no. 1, pp. 29-33. https://doi.org/10.1006/gyno.1995.1005
Kilgore, Larry ; Partridge, Edward E. ; Alvarez, Ronald D. ; Austin, J. Maxwell ; Shingleton, Hugh M. ; Noojin, Frank ; Conner, Wendy. / Adenocarcinoma of the endometrium : Survival comparisons of patients with and without pelvic node sampling. In: Gynecologic oncology. 1995 ; Vol. 56, No. 1. pp. 29-33.
@article{22fbff26f8d1413c87f90659f0e2848f,
title = "Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling",
abstract = "From 1969 to 1990, 649 patients with adenocarcinoma of the endometrium were surgically managed by gynecologic oncologists from the University of Alabama at Birmingham. All patients underwent TAH-BSO and washings. Two hundred twelve patients had multiple-site pelvic node sampling (mean number of nodes, 11), 205 patients had limited site pelvic node sampling (mean number of nodes, 4), and in 208 patients, nodes were not sampled. Historical prognostic features, including tumor grade, depth of invasion, adnexal metastasis, cervical involvement, and positive cytology, were equally distributed in the three groups. Mean follow-up was 3 years. Patients undergoing multiple-site pelvic node sampling had significantly better survival than patients without node sampling (P = 0.0002). When patients were categorized as low risk (disease confined to the corpus) or as high risk (disease in the cervix, adnexa, uterine serosa, or washings) multiple-site pelvic node sampling again provided a significant survival advantage compared to patients without node sampling (high risk, P = 0.0006; low risk, P = 0.026). In a comparison of patients receiving whole pelvic radiation for grade III lesions or deep myometrial invasion, patients with multiple-site pelvic node sampling had better survival than those in whom nodes were not sampled (P = 0.0027). The significant survival advantage for patients having multiple-site node sampling, overall and in high- and low-risk groups, strongly suggests a therapeutic benefit. Additionally, adjuvant therapy may be more appropriately directed in these patients.",
author = "Larry Kilgore and Partridge, {Edward E.} and Alvarez, {Ronald D.} and Austin, {J. Maxwell} and Shingleton, {Hugh M.} and Frank Noojin and Wendy Conner",
year = "1995",
month = "1",
day = "1",
doi = "10.1006/gyno.1995.1005",
language = "English (US)",
volume = "56",
pages = "29--33",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Adenocarcinoma of the endometrium

T2 - Survival comparisons of patients with and without pelvic node sampling

AU - Kilgore, Larry

AU - Partridge, Edward E.

AU - Alvarez, Ronald D.

AU - Austin, J. Maxwell

AU - Shingleton, Hugh M.

AU - Noojin, Frank

AU - Conner, Wendy

PY - 1995/1/1

Y1 - 1995/1/1

N2 - From 1969 to 1990, 649 patients with adenocarcinoma of the endometrium were surgically managed by gynecologic oncologists from the University of Alabama at Birmingham. All patients underwent TAH-BSO and washings. Two hundred twelve patients had multiple-site pelvic node sampling (mean number of nodes, 11), 205 patients had limited site pelvic node sampling (mean number of nodes, 4), and in 208 patients, nodes were not sampled. Historical prognostic features, including tumor grade, depth of invasion, adnexal metastasis, cervical involvement, and positive cytology, were equally distributed in the three groups. Mean follow-up was 3 years. Patients undergoing multiple-site pelvic node sampling had significantly better survival than patients without node sampling (P = 0.0002). When patients were categorized as low risk (disease confined to the corpus) or as high risk (disease in the cervix, adnexa, uterine serosa, or washings) multiple-site pelvic node sampling again provided a significant survival advantage compared to patients without node sampling (high risk, P = 0.0006; low risk, P = 0.026). In a comparison of patients receiving whole pelvic radiation for grade III lesions or deep myometrial invasion, patients with multiple-site pelvic node sampling had better survival than those in whom nodes were not sampled (P = 0.0027). The significant survival advantage for patients having multiple-site node sampling, overall and in high- and low-risk groups, strongly suggests a therapeutic benefit. Additionally, adjuvant therapy may be more appropriately directed in these patients.

AB - From 1969 to 1990, 649 patients with adenocarcinoma of the endometrium were surgically managed by gynecologic oncologists from the University of Alabama at Birmingham. All patients underwent TAH-BSO and washings. Two hundred twelve patients had multiple-site pelvic node sampling (mean number of nodes, 11), 205 patients had limited site pelvic node sampling (mean number of nodes, 4), and in 208 patients, nodes were not sampled. Historical prognostic features, including tumor grade, depth of invasion, adnexal metastasis, cervical involvement, and positive cytology, were equally distributed in the three groups. Mean follow-up was 3 years. Patients undergoing multiple-site pelvic node sampling had significantly better survival than patients without node sampling (P = 0.0002). When patients were categorized as low risk (disease confined to the corpus) or as high risk (disease in the cervix, adnexa, uterine serosa, or washings) multiple-site pelvic node sampling again provided a significant survival advantage compared to patients without node sampling (high risk, P = 0.0006; low risk, P = 0.026). In a comparison of patients receiving whole pelvic radiation for grade III lesions or deep myometrial invasion, patients with multiple-site pelvic node sampling had better survival than those in whom nodes were not sampled (P = 0.0027). The significant survival advantage for patients having multiple-site node sampling, overall and in high- and low-risk groups, strongly suggests a therapeutic benefit. Additionally, adjuvant therapy may be more appropriately directed in these patients.

UR - http://www.scopus.com/inward/record.url?scp=0028942190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028942190&partnerID=8YFLogxK

U2 - 10.1006/gyno.1995.1005

DO - 10.1006/gyno.1995.1005

M3 - Article

VL - 56

SP - 29

EP - 33

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -